NRAS G12C
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene NRAS
Variant G12C
Impact List missense
Protein Effect loss of function - predicted
Gene Variant Descriptions NRAS G12C is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G12C does not result in activation of Erk1/2 or Stat5 signaling but results in transformation in culture (PMID: 35211470) and can be predicted to confer a loss of function to the Nras protein based on the effects of HRAS G12C and KRAS G12C, which result in a loss of response to GTPase-activating proteins, and transformation of cultured cells (PMID: 26037647, PMID: 6092966).
Associated Drug Resistance
Category Variants Paths

NRAS mutant NRAS act mut NRAS G12C

NRAS mutant NRAS exon2 NRAS G12X NRAS G12C

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_002524.5
gDNA chr1:g.114716127C>A
cDNA c.34G>T
Protein p.G12C
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_002524 chr1:g.114716127C>A c.34G>T p.G12C RefSeq GRCh38/hg38
NM_002524.4 chr1:g.114716127C>A c.34G>T p.G12C RefSeq GRCh38/hg38
NM_002524.5 chr1:g.114716127C>A c.34G>T p.G12C RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NRAS G12C rectum cancer predicted - sensitive Panitumumab + Sotorasib Case Reports/Case Series Actionable In a clinical case study, the combination of Lumakras (sotorasib) and Vectibix (panitumumab) resulted in a partial response after 12 weeks in a patient with metastatic rectal cancer harboring NRAS G12C (PMID: 37262393). 37262393
NRAS G12C Advanced Solid Tumor sensitive JDQ443 Preclinical - Cell culture Actionable In a preclinical study, JDQ443 inhibited viability of cultured cells expressing NRAS G12C (PMID: 38236605). 38236605
NRAS G12C Advanced Solid Tumor sensitive Sotorasib Preclinical - Cell culture Actionable In a preclinical study, Lumakras (sotorasib) inhibited viability of cultured cells expressing NRAS G12C (PMID: 38236605). 38236605
NRAS G12C colorectal cancer predicted - sensitive Panitumumab + Sotorasib Case Reports/Case Series Actionable In clinical case study, treatment with the combination of Lumakras (sotorasib) and Vectibix (panitumumab) resulted in a decrease in the size of liver metastases and improved serum markers after 2 months of treatment in a patient with colorectal cancer harboring NRAS G12C (PMID: 38236605). 38236605
NRAS G12C Advanced Solid Tumor sensitive RM-018 Preclinical - Cell culture Actionable In a preclinical study, RM-018 inhibited viability of cultured cells expressing NRAS G12C (PMID: 38236605). 38236605
NRAS G12C leukemia predicted - sensitive Sotorasib Preclinical - Biochemical Actionable In a preclinical study, Lumakras (sotorasib) inhibited downstream signaling in leukemia cells harboring NRAS G12C in culture (PMID: 38236605). 38236605
NRAS G12C Advanced Solid Tumor sensitive Glecirasib Preclinical - Cell culture Actionable In a preclinical study, Glecirasib (JAB-21822) treatment inhibited viability of cells expressing NRAS G12C in culture (PMID: 40304209). 40304209